ADT May Offer Some Protection From COVID-19 in Men with Prostate Cancer

[Seabird12]

A STUDY of men with prostate cancer in Italy suggests that men with prostate cancer who were taking ADT were 4 times less likely to be infected with the coronavirus than men who were not on ADT (ANDROGEN DEPRIVATION THERAPY), and 5 times less likely to die. These new findings are a game-changer and may lead to potential treatments for COVID-19, even in men without prostate cancer.

Prof. Andrea Alimonti and team looked at more than 9000 patients with confirmed COVID-19 infection in Veneto, Italy; they also used data on all cancer patients in the region for comparison. Among all prostate cancer patients, only 4 out of 5,273 men on ADT developed COVID-19 infection. None of the men died. Among 37,161 men with prostate cancer who were not receiving ADT, 114 developed COVID-19 and 18 died.